MedTrace Logo

Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

NCT07457190 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-03-10

No results posted yet for this study

Summary

This study adopts a non-randomized, open label, parallel, single-dose design to evaluate the safety and pharmacokinetic characteristics of Buagafuran capsules in participants with hepatic impairment.

Conditions

  • Generalized Anxiety Disorder

Interventions

DRUG

Buagafuran

participants to receive Buagafuran capsules 30 mg on an empty stomach on the morning of Day1

Sponsors & Collaborators

  • Beijing Union Pharmaceutical Factory Ltd

    lead INDUSTRY

Principal Investigators

  • Hong Zhang · The First Hospital of Jilin University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2026-08-31
Completion
2026-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07457190 on ClinicalTrials.gov